# US 2015/0148293 A1 · Fibroblast growth factor mutants having improved functional half-life and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148293 A1
- Document ID: US20150148293A1
- Status: Published application
- Kind: A1
- Application number: 14/593,107
- Filed: 2015-01-09
- Published: 2015-05-28
- Earliest claimed: 2009-05-20
- Assignees: The Florida State University Research Foundation, Inc.
- Applicants: Florida State University Research Foundation
- Inventors: MICHAEL BLABER; JIHUN LEE
- Web page: https://patentgrep.com/patent/US20150148293A1

## CPC

- C07K 14/50: Fibroblast growth factor [FGF]
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07K 14/501: {acidic FGF [aFGF]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/21: containing a His-tag
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human FGF-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human FGF-1 with a tryptophan (based on the 140 amino acid numbering scheme of human FGF-1) are provided. Other amino acid mutations or substitutions may be combined. Polynucleotide sequences encoding the mutant FGF proteins and host cells containing such polynucleotide sequences are provided. Methods of administering a mutant FGF protein to an individual to treat an ischemic condition or disease or a wound or tissue injury are also provided.

## Claims

### Claim 1

A mutant fibroblast growth factor (FGF) protein having a polypeptide sequence that is at least 90% identical to the polypeptide sequence of wild-type human FGF-1 protein (SEQ ID NO: 13), and wherein the numbering of the amino acid positions is based on the numbering scheme for the 140 amino acid form of human FGF-1.

### Claim 2 (depends on 1)

The mutant FGF protein of claim 1, wherein the mutant FGF protein has a polypeptide sequence that is at least 95% identical to the polypeptide sequence of wild-type human FGF-1 protein (SEQ ID NO: 13).

### Claim 3 (depends on 1)

The mutant FGF protein of claim 1, wherein the mutant FGF protein binds specifically to at least one FGF receptor (FGFR) and triggers growth or proliferation of cultured fibroblast cells.

### Claim 4 (depends on 1)

The mutant FGF protein of claim 1, wherein the mutant FGF protein has a greater functional half-life than wild-type human FGF-1 according to a cultured fibroblast proliferation assay.

### Claim 5 (depends on 1)

The mutant FGF protein of claim 1, wherein the protein structure of the mutant FGF protein has a greater thermodynamic stability than wild-type human FGF-1.

### Claim 6 (depends on 5)

The mutant FGF protein of claim 5, wherein the mutant FGF protein has a ΔGunfolding value greater than that of wild-type human FGF-1 such that
ΔΔG=ΔGunfolding wild-type−ΔGunfolding mutant<0
according to one or more of the following methods: isothermal equilibrium denaturation, differential scanning calorimetry, or temperature-dependent spectroscopy.

### Claim 7 (depends on 1)

A functional fragment of the mutant FGF protein of claim 1, wherein the fragment of the mutant FGF protein binds specifically to at least one FGF receptor (FGFR) and triggers growth or proliferation of fibroblasts, endothelial cells, chondrocytes, osteoblasts, myoblasts, smooth muscle cells, glial cells, or neuroblasts.

### Claim 8 (depends on 1)

A polynucleotide sequence encoding the mutant FGF protein of claim 1.

### Claim 9 (depends on 8)

A host cell containing the polynucleotide sequence of claim 8.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the mutant FGF protein of claim 1 and a pharmaceutically acceptable carrier.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

A mutant fibroblast growth factor (FGF) protein having a polypeptide sequence that is at least 90% identical to the polypeptide sequence of wild-type human FGF-1 protein (SEQ ID NO: 13), and wherein the numbering of the amino acid positions is based on the numbering scheme for the 140 amino acid form of human FGF-1;
the method, comprising the following steps:
(a) identifying an individual having an ischemic condition or disease; and
(b) administering to the individual a composition comprising the mutant FGF protein; wherein the composition is administered locally at or near the site of the ischemic condition or disease within the body of the individual.

### Claim 14

A mutant fibroblast growth factor (FGF) protein having a polypeptide sequence that is at least 90% identical to the polypeptide sequence of wild-type human FGF-1 protein (SEQ ID NO: 13), and wherein the numbering of the amino acid positions is based on the numbering scheme for the 140 amino acid form of human FGF-1;
the method, comprising the following steps:
(a) identifying an individual having an ischemic condition or disease; and
(b) administering to the individual a composition comprising the mutant FGF protein; wherein the composition is administered locally at or near a site within the body of the individual causing the ischemic condition or disease.

### Claim 15

(canceled)

### Claim 16

A method comprising the following steps:
(a) identifying an individual having a wound or tissue damage; and
(b) administering to the individual a composition comprising a mutant fibroblast growth factor (FGF) protein in a therapeutically effective amount to thereby improve the quality and/or rate of healing or repairing of the wound or the tissue damage compared to an untreated wound and/or untreated tissue damage,
wherein the mutant FGF protein is a member of the group consisting of: a mutant FGF protein having a polypeptide sequence that is at least 90% identical to the polypeptide sequence of wild-type human FGF-1 protein (SEQ ID NO: 13),
wherein the numbering of the amino acid positions is based on the numbering scheme for the 140 amino acid form of human FGF-1, and
wherein step (b) comprises triggering the growth and/or proliferation of one or more members of the group consisting of: fibroblast cells, neuronal cells, neuroblast cells, endothelial cells, chondrocytes, osteoblasts, myoblasts, smooth muscle cells and glial cells.

### Claim 17 (depends on 16)

The method of claim 16, wherein the wound or tissue damage is due to a traumatic injury or an immunologic disorder.

### Claim 18 (depends on 16)

The method of claim 16, wherein the wound or tissue damage is due to stroke, myocardial infarction, acute transverse myelitis (ATM), idiopathic transverse myelitis (ITM), brachial plexus injury, spinal cord injury or peripheral nerve injury.

### Claim 19 (depends on 16)

The method of claim 16, wherein the composition is administered locally at or near the site of the wound or tissue damage within the body of the individual.

### Claim 20 (depends on 16)

The method of claim 16, wherein the mutant FGF protein has a polypeptide sequence that is at least 95% identical to the polypeptide sequence of wild-type human FGF-1 protein (SEQ ID NO: 13).

### Claim 21 (depends on 16)

The method of claim 16, wherein the mutant FGF protein binds specifically to at least one FGF receptor (FGFR) and triggers growth or proliferation of cultured fibroblast cells.

### Claim 22 (depends on 16)

The method of claim 16, wherein the mutant FGF protein has a greater functional half-life than wild-type human FGF-1 according to a cultured fibroblast proliferation assay.

### Claim 23 (depends on 16)

The method of claim 16, wherein the protein structure of the mutant FGF protein has a greater thermodynamic stability than wild-type human FGF-1.

### Claim 24 (depends on 23)

The method of claim 23, wherein the mutant FGF protein has a ΔGunfolding value greater than that of wild-type human FGF-1 such that
ΔΔG=ΔGunfolding wild-type−ΔGunfolding mutant<0
according to one or more of the following methods: isothermal equilibrium denaturation, differential scanning calorimetry or temperature-dependent spectroscopy.

### Claim 25 (depends on 16)

The method of claim 16, wherein the therapeutically effective amount of the mutant FGF protein is an amount effective to increase blood flow, angiogenesis, and/or vascularization within or to a particular tissue or region of the body of the individual.
